{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:44:03Z","timestamp":1759412643791},"reference-count":47,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Key Program for Infectious Disease of China","award":["2013ZX10004221"],"award-info":[{"award-number":["2013ZX10004221"]}]},{"name":"State Key Laboratory of Infectious Disease Prevention and Control","award":["2015SKLID502"],"award-info":[{"award-number":["2015SKLID502"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81602903"],"award-info":[{"award-number":["81602903"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.vaccine.2017.03.057","type":"journal-article","created":{"date-parts":[[2017,3,25]],"date-time":"2017-03-25T14:00:44Z","timestamp":1490450444000},"page":"2343-2350","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prevalence of factor H Binding Protein sub-variants among Neisseria meningitidis in China"],"prefix":"10.1016","volume":"35","author":[{"given":"Fenglin","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingqing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zundong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhujun","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.03.057_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.057_b0010","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1086\/651505","article-title":"Population structure and capsular switching of invasive neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era\u2014United States, 2000\u20132005","volume":"201","author":"Harrison","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.057_b0015","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3201\/eid2106.140687","article-title":"Sequence type 4821 clonal complex serogroup B Neisseria meningitidis in China, 1978\u20132013","volume":"21","author":"Zhu","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.057_b0020","doi-asserted-by":"crossref","DOI":"10.1007\/s40121-016-0107-0","article-title":"Meningococcal vaccinations","author":"Crum-Cianflone","year":"2016","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2017.03.057_b0025","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"322","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.03.057_b0030","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1128\/IAI.63.5.1906-1913.1995","article-title":"Human immunoglobulin M paraproteins cross-reactive with Neisseria meningitidis group B polysaccharide and fetal brain","volume":"63","author":"Azmi","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.03.057_b0035","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1084\/jem.147.3.629","article-title":"Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model","volume":"147","author":"Frasch","year":"1978","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.03.057_b0040","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1128\/IAI.46.2.408-414.1984","article-title":"Development of a Neisseria meningitidis group B serotype 2b protein vaccine and evaluation in a mouse model","volume":"46","author":"Wang","year":"1984","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.03.057_b0045","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4161\/hv.24129","article-title":"Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV) Lessons from past programs and implications for the future","volume":"9","author":"Holst","year":"2013","journal-title":"Hum Vacc Immunother"},{"key":"10.1016\/j.vaccine.2017.03.057_b0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis","volume":"27","author":"Holst","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.057_b0055","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4161\/hv.4513","article-title":"Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them","volume":"3","author":"Holst","year":"2007","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2017.03.057_b0060","first-page":"110","article-title":"Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH Ann"},{"key":"10.1016\/j.vaccine.2017.03.057_b0065","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0264-410X(94)00037-N","article-title":"Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease","volume":"13","author":"Boslego","year":"1995","journal-title":"Vaccine"},{"issue":"30","key":"10.1016\/j.vaccine.2017.03.057_b0070","article-title":"A \u2018tailor made\u2019 vaccine trialled as part of public health response to group B meningococcal epidemic in New Zealand","volume":"7","author":"Holst","year":"2003","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2017.03.057_b0075","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1586\/14760584.2014.880341","article-title":"Neisseria Meningitidis B vaccines: recent advances and possible immunization policies","volume":"13","author":"Gasparini","year":"2014","journal-title":"Exp Rev Vacc"},{"key":"10.1016\/j.vaccine.2017.03.057_b0080","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20021911","article-title":"Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870","volume":"197","author":"Masignani","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.03.057_b0085","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing","volume":"287","author":"Pizza","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.03.057_b0090","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1016\/S0264-410X(00)00554-5","article-title":"Reverse vaccinology, a genome-based approach to vaccine development","volume":"19","author":"Rappuoli","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.057_b0095","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the Neisseria meningitidis 2086 lipoprotein","volume":"72","author":"Fletcher","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.03.057_b0100","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40259-013-0029-2","article-title":"Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero\u00ae): a review of its use in primary and booster vaccination","volume":"27","author":"Carter","year":"2013","journal-title":"BioDrugs"},{"key":"10.1016\/j.vaccine.2017.03.057_b0105","doi-asserted-by":"crossref","DOI":"10.1007\/s40259-015-0139-0","article-title":"Bivalent rLP2086 vaccine (Trumenba\u00ae): a review in active immunization against invasive meningococcal group B disease in individuals aged 10\u201325 years","author":"Shirley","year":"2015","journal-title":"BioDrugs"},{"key":"10.1016\/j.vaccine.2017.03.057_b0110","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/IAI.01191-08","article-title":"Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera","volume":"77","author":"Granoff","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.03.057_b0115","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.177.1.501","article-title":"The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance","volume":"177","author":"Madico","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.03.057_b0120","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1099\/mic.0.027995-0","article-title":"Variation of the factor H-binding protein of Neisseria meningitidis","volume":"155","author":"Brehony","year":"2009","journal-title":"Microbiology"},{"key":"10.1016\/j.vaccine.2017.03.057_b0125","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1586\/14760584.2015.1016915","article-title":"Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen","volume":"14","author":"Seib","year":"2015","journal-title":"Exp Rev Vacc"},{"key":"10.1016\/j.vaccine.2017.03.057_b0130","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1016\/j.vaccine.2010.06.083","article-title":"Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease","volume":"28","author":"Jiang","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.057_b0135","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1586\/14760584.2015.1015997","article-title":"Neisseria meningitidis serogroup B bivalent factor H binding protein vaccine","volume":"14","author":"Brendish","year":"2015","journal-title":"Exp Rev Vacc"},{"key":"10.1016\/j.vaccine.2017.03.057_b0140","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.057_b0145","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4161\/hv.7.0.14564","article-title":"Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease","volume":"7","author":"Harris","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2017.03.057_b0150","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1086\/597806","article-title":"Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa","volume":"199","author":"Beernink","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.057_b0155","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.vaccine.2015.12.034","article-title":"A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine","volume":"34","author":"Pajon","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.057_b0160","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jinf.2014.07.022","article-title":"Clonal characteristics of invasive Neisseria meningitidis following initiation of an A+C vaccination program in China, 2005\u20132012","volume":"70","author":"Zhou","year":"2015","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2017.03.057_b0165","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.3201\/eid1909.130160","article-title":"Spread of Neisseria meningitidis serogroup W clone, China","volume":"19","author":"Zhou","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.057_b0170","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1017\/S0950268811001865","article-title":"Distribution of serogroups and sequence types in disease-associated and carrier strains of Neisseria meningitidis isolated in China between 2003 and 2008","volume":"140","author":"Zhou","year":"2012","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2017.03.057_b0175","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1128\/JCM.42.4.1764-1765.2004","article-title":"PCR-based assay for detection of Neisseria meningitidis capsular serogroups 29E, X, and Z","volume":"42","author":"Bennett","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2017.03.057_b0180","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1128\/JCM.00918-11","article-title":"Development of a multiplex PCR assay for detection and genogrouping of Neisseria meningitidis","volume":"50","author":"Zhu","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2017.03.057_b0185","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.vaccine.2005.11.006","article-title":"Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens","volume":"24","author":"Jacobsson","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.057_b0190","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1128\/CVI.00055-11","article-title":"Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein","volume":"18","author":"Lucidarme","year":"2011","journal-title":"Clin Vacc Immunol"},{"key":"10.1016\/j.vaccine.2017.03.057_b0195","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1073\/pnas.95.6.3140","article-title":"Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms","volume":"95","author":"Maiden","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.03.057_b0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001302","article-title":"Meningococcal factor H binding proteins in epidemic strains from Africa: Implications for vaccine development","volume":"5","author":"Pajon","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2017.03.057_b0205","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1016\/j.vaccine.2011.04.092","article-title":"Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States","volume":"29","author":"Wang","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.057_b0210","doi-asserted-by":"crossref","first-page":"e33016","DOI":"10.1371\/journal.pone.0033016","article-title":"Molecular Epidemiology of Neisseria meningitidis Serogroup B in Brazil","volume":"7","author":"de Filippis","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.03.057_b0215","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2017.03.057_b0220","doi-asserted-by":"crossref","first-page":"201521142","DOI":"10.1073\/pnas.1521142113","article-title":"Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined","volume":"113","author":"Biagini","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2017.03.057_b0225","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.vaccine.2015.11.070","article-title":"High predicted strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland","volume":"34","author":"Wa\u015bko","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.057_b0230","first-page":"825","article-title":"Epidemiological analysis on serogroup Y Neisseria meningitidis firstly isolated from patient in Tianjin","volume":"50","author":"Guo","year":"2016","journal-title":"Chin J Prev Med"},{"key":"10.1016\/j.vaccine.2017.03.057_b0235","first-page":"579","article-title":"Investigation and response for the first case of group X meningococcal disease in Zhejiang province","volume":"49","author":"Zhang","year":"2015","journal-title":"Chin J Prev Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17303742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17303742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T11:10:07Z","timestamp":1601809807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17303742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":47,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0264410X17303742"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.057","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of factor H Binding Protein sub-variants among Neisseria meningitidis in China","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}